Impact of Prior Somatostatin Analogue (SSA) Use on Progression-free Survival (PFS) in Patients with Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: A Secondary Analysis from the RADIANT-4 Study
#1503
Introduction: In the RADIANT-4 study, everolimus (EVE) reduced the risk of disease progression or death by 52% vs placebo (PBO; P<0.00001) in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET of lung/GI tract.
Aim(s): To assess the impact of prior SSA on PFS in the RADIANT-4 study.
Materials and methods: Pts were randomized (2:1) to receive EVE 10 mg/day or PBO. This analysis reports baseline characteristics, PFS, and safety by prior SSA use.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Buzzoni R
Authors: Buzzoni R, Carnaghi C, Pommier R, Fazio N, Singh S,
Keywords: everolimus, SSA, nonfunctional NET,
To read the full abstract, please log into your ENETS Member account.